Publikacje

Ważniejsze publikacje Kliniki Neurologii WUM z okresu 2006-2016, publikacje z lat 2016-2020 dostępne w ramach portalu WUM: https://publikacje.wum.edu.pl/MainPage- kod jednostki NZP.

1. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, Larsen JP, Lees A, Oertel W, Poewe W, Rascol O, Sampaio C- Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006; 13: 1170-1186

2. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, Larsen JP, Lees A, Oertel W, Poewe W, Rascol O, Sampaio C - Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1186-1203

3. Friedman A, Galazka-Friedman J, Bauminger ER- Iron as a trigger of neurodegeneration in Parkinson’s disease. In: Handbook of Clinical Neurology, vol. 83, Koller W & Melamed E, eds, Parkinson's disease and related disorders, ISBN 0444519009., Elsevier, Edinburgh 2007; pp.493-506

4. Koziorowski D, Friedman A, Arosio P, Santambrogio P, Dziewulska D- ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson’s disease and Incidental Lewy Body compared to control. Park Rel Disord 2007; 13: 214-218

5. Bruno MK, Lee, H-Y, Auburger GWJ, Friedman A, Nielsen JE, Lang AE, Bertini E, Van Bogaert P, Averyanov Y, Hallett M, Gwin-Hardy K, Sorenson B, Pandolfo M, Kwiecinski H, Servidei S, Fu Y-H, Ptacek L- Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesias. Neurology 2007; 68: 1782-1789

6. Szczaluba K, Jurek M, Milewski M, Friedman A, Kadziolka B, Szolna A, Bal J, Mazurczak T - Clinical characteristics of carriers of a GAG deletion in the DYT1 gene amongst Polish patients with primary dystonia. Eur J Neurol. 2007; 14: 659-662

7. Slawek J, Friedman A, Potulska A, Krystkowiak P, Gervais C, Banach M, Ochudlo S, Budrewicz S, Reclawowicz D, Rynkowski M, Opala G- Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol 2007; 22: 95-100

8. Koziorowski D, Friedman A- Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease. Mov Disord. 2007; 22: 1033-1036.

9. Gawrys L, Szatkowska I, Jamrozik Z, Janik P, Friedman  A, and Kaczmarek L.Nonverbal deficits in explicit and implicit memory of Parkinson’s disease patients. Acta Neurobiol. Exp. 2008; 68: 58-72

10. Selikhova M, Fedoryshyn L, Matviyenko Y, Komnatska I, Kyrylchuk M, Krolicki L, Friedman A, Taylor A, Jäger HR, Lees A, Sanotsky Y- Parkinsonism and dystonia caused by the illicit use of ephedrone--a longitudinal study. Mov Disord. 2008; 23: 2224-2231 (IF-3.898)

11. Friedman A, Zakrzewska-Pniewska B, Domitrz I, H-Y Lee, Ptacek L, Kwiecinski H- Paroxysmal Non-Kinesigenic Dyskinesia caused by the mutation of MR-1 in a large Polish kindred. Eur Neurol 2009; 61: 39-41

12. Galazka-Friedman J, Bauminger ER, Szlachta K, Schweitzer K, Wszolek Z, Dickson D, Friedman A- Mössbauer studies of pathological brain tissues affected by PSP disease. Acta Phys Pol 2009; 115: 431-433

13. Galazka-Friedman J, Friedman A, Bauminger ER- Iron in the brain. Hyperfine Interact 2009; 189: 31-37

14. Szczałuba K, Jurek M, Szczepanik E, Friedman A, Milewski M, Bal J, Mazurczak T - A family with paroxysmal nonkinesigenic dyskinesia: genetic and treatment issues. Pediatr Neurol 2009; 41: 135-138

15. Friedman A, Galazka-Friedman J, Koziorowski D- Iron as a cause of Parkinson disease – a myth or a well established hypothesis? Park Rel Disord 2009; 15 (suppl): S212-S214

16. Koziorowski D, Hoffman-Zacharska D, Slawek J, Szirkowiec W, Janik P, Bal J, Friedman A- Low frequency of the PARK2 gene mutations in Polish patients with early-onset form of Parkinson disease. Park Rel Disord 2010; 16: 136-138

17. Wypijewska A, Galazka-Friedman J, Bauminger ER, Wszolek ZK, Schweitzer KJ, Dickson DW,    Jaklewicz A, Elbaum D, Friedman A- Iron and reactive oxygen species activity in parkinsonian substantia nigra. Park Rel Disord 2010; 16: 329-333

18. Kaca-Oryńska M, Tomasiuk R, Friedman A- Neuron-specific enolase and S 100B protein as predictors of outcome in ischaemic stroke. Neurol Neurochir Pol 2010; 44: 459-463

19. Mądry J, Hoffman-Zacharska D, Królicki L, Jakuciński M, Friedman A- PLP1 gene duplication as a cause of the classic form of Pelizaeus-Merzbacher disease – case report. Neurol Neurochir Pol 2010; 44: 511-515

20. Oertel WH, Berardelli A,  Bloem BR,  Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Ferreira JJ, Friedman A, Kanovsky P, Kostic V,  Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schüpbach M, Tolosa E, Trenkwalder C- Early (uncomplicated) Parkinson ’ s disease. European Handbook of Neurological Management: Volume 1, chapter 14, pp. 217-236, 2nd edition. Edited by N. E. Gilhus, M. P. Barnes and M. Brainin. 2011 Blackwell Publishing Ltd.

21. Oertel WH, Berardelli A,  Bloem BR,  Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Ferreira JJ, Friedman A, Kanovsky P, Kostic V,  Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schüpbach M, Tolosa E, Trenkwalder C- Late (complicated) Parkinson ’ s disease. European Handbook of Neurological Management: Volume 1, chapter 15, pp. 237-267, 2nd edition. Edited by N. E. Gilhus, M. P. Barnes and M. Brainin. 2011 Blackwell Publishing Ltd.

22. Gałązka-Friedman J, Bauminger ER, Szlachta K, Koziorowski D, Tomasiuk R, Jaklewicz A, Wszolek ZK, Dickson D, Kaplinska K, Friedman A- Iron in Alzheimer and control hippocampi – Mössbauer, atomic absorption and ELISA studies. Acta Phys Pol 2011; 119: 81-83

23. Koziorowski D, Rajkiewicz M, Sułek-Piątkowska A, Zaremba J, Kaca-Oryńska M, Mandat T, Friedman A- The familial occurrence of the FXTAS caused by premutation in  the FMR1 gene. Neur Neurochir Pol 2011; 45: 391-398

24. Friedman A, Arosio P, Finazzi D, Koziorowski D, Galazka-Friedman J- Ferritin as an important player in neurodegeneration, Park Rel Disord. 2011; 17: 423-430

25.  Galazka-Friedman J, Friedman A- Role of iron in pathogenesis of Parkinson disease. BioTechnologia 2011; 92: 153-158

26. Sadowski K, Szlachta K, Serafin-Król M, Galazka-Friedman J, Friedman A - Brain tissue echogenicity -  implications for substantia nigra studies in parkinsonian patients. J Neural Trans 2012; 119: 363-367

27. Szlachta K, Sadowski K, Kuliński R, Galazka-Friedman J, Friedman A- Different signals of magnetic resonance imaging and ultrasound from substantia nigra in Parkinson disease and control – is iron the cause? Acta Phys Pol A 2012: 121: 454-456

28. Galazka-Friedman J, Bauminger ER, Szlachta K, Friedman A- The role of iron in neurodegeneration – Mössbauer spectroscopy, electron microscopy, enzyme-linked immunosorbent assay and neuroimaging studies. J Phys Condens Matter 2012; 24: 244101(7pp) doi:10.1088/0953-8984/24/24/244106

29. Szlufik S, Koziorowski D, Tomasiuk R, Friedman A- Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. Cytokine 2012; 60: 762-766

30. Friedman A, Galazka-Friedman J- The history of the research of iron in parkinsonian substantia nigra. J Neural Transm 2012; 119: 1507-1510

31. Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schüpbach M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH- Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013; 20: 5-15

32. Koziorowski D, Hoffman-Zacharska D, Sławek J, Jamrozik Z, Janik P, Potulska-Chromik A, Roszmann A, Tataj R, Bal J, Friedman A- Incidence of mutations in the PARK2, PINK1, PARK7 genes in Polish early-onset Parkinson disease patients. Neurol Neurochir Pol. 2013; 47: 319-324.

33. Hoffman-Zacharska D, Koziorowski D, Ross OA, Milewski M, Poznański J, Jurek M, Wszolek ZK, Soto-Ortolaza A, Sławek J, Janik P, Jamrozik Z, Potulska-Chromik A, Jasińska-Myga B, Opala G, Krygowska-Wajs A, Czyżewski K, Dickson DW, Bal J, Friedman A- Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson's disease. Park Relat Disord. 2013; 19: 1057-60

34. Galazka-Friedman J, Bauminger ER, Friedman A- Iron in neurodegeneration. In: Sharma VK, Klingelhöfer G, Nishida T (eds.) Mössbauer spectroscopy- Applications in chemistry, biology and nanotechnology. Wiley 2013; 324-332

35. Friedman A, Sanotsky Y, Wolters E- Drug-induced parkinsonism. In: Wolters and Baumann (eds.) Parkinson disease and other movement disorders. Vu University Press, Amsterdam 2014, pp. 373-384

36. Tomasiuk R, Szlufik S, Friedman A, Koziorowski D- Ropinirole treatment in Parkinson’s disease associated with higher serum level of inflammatory biomarker NT-proCNP. Neuroscience Letters 2014; 566: 147–150

37. Jurek M, Hoffman-Zacharska D, Koziorowski D, Mądry J, Friedman A, Bal J- Intrafamilial variability of the primary dystonia DYT6 phenotype caused by p.Cys5Trp mutation in THAP1 gene. Neurol Neurochir Pol. 2014; 48: 254-257.

38. Nitkowska M, Czyżyk M, Friedman A- Reproductive life characteristics in females affected with Parkinson's disease and in healthy control subjects - a comparative study on Polish population. Neur Neurochir Pol 2014; 48: 322-327

39. Galazka-Friedman J, Friedman A- The Possible Role of Iron in Neurodegeneration. In: A. Dietrich-Muszalska et al. (eds.), Studies on Psychiatric Disorders, Oxidative Stress in Applied Basic Research and Clinical Practice, Springer Science+Business Media New York 2015

40. Sadowski K, Serafin-Król M, Szlachta K, Friedman A- Basal ganglia echogenicity in tauopathies. J Neural Transm 2015; 122: 863-865

41. Nitkowska M, Tomasiuk R, Czyżyk M, Friedman A- Prolactin and sex hormones levels in males with Parkinson’s disease. Acta Neurol Scand 2015; 131: 411-416

42. Dutkiewicz J, Szlufik S, Nieciecki M, Charzyńska I, Królicki L, Smektała P, Friedman A- Small intestine dysfunction in Parkinson’s disease. J Neural Trans 2015; 122: 1659-1661

43. Koziorowski D, Szlufik S, Mandat T, Kloda M, Duszynska-Was K, Drzewinska A, Friedman A- Improvement in ephedrone parkinsonism after globus pallidus pars interna Deep Brain Stimulation implantation. Mov Disord Clin Pract 2015,DOI:10.1002/mdc3.12248

44. Kwiatek-Majkusiak J, Dickson DW, Tacik P, Aoki N, Tomasiuk R, Koziorowski D, Friedman A- Relationships between typical histopathological hallmarks and the ferritin in the hippocampus from patients with Alzheimer’s disease. Acta Neurobiol Exp 2015; 75: 391-411

45. Jamrozik Z, Ługowska A, Koziorowski D, Friedman A, Sławek J, Janik P, Potulska-Chromik A, Kuzma-Kozakiewicz M, Wiśniewska A, Szubiga M, Rudzińska M, Szczudlik A, Hoffman-Zachariasz D- Beta-glucocerebrosidase gene mutation P.Asn409Ser and P.Leu438Pro in Polish patients with Parkinson’s disease. J Neurol Neurosci 2015; 6 (4): 54

46. Valadas A, Contarino MF, Albanese A, Bhatia KP, Falup-Pecurariu C, Forsgren L, Friedman A, Giladi N, Hutchinson M, Kostic VS, Krauss JK, Lokkegaard A, Marti MJ, Milanov I, Pirtosek Z, Relja M, Skorvanek M, Stamelou M, Stepens A, Tamás G, Taravari A, Tzoulis C, Vandenberghe W, Vidailhet M, Ferreira JJ, Tijssen MA- Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. Eur J Neurol. 2016; 23: 772-779

47. Koziorowski D, Szlufik S, Mandat T, Kłoda M, Duszyńska-Was K, Drzewińska A, Friedman A- Improvement in Ephedrone Parkinsonism After Global Pallidus Pars Interna Deep Brain Stimulation Implantation. Movement Disord Clinical Pract 2016

48. Przybyszewski A., Szlufik S., Dutkiewicz J., Habela P., Koziorowski D. Machine Learning on the Video Basis of Slow Pursuit Eye Movements Can Predict Symptom Development in Parkinson’s Patients 9012 of the series Lecture Notes in Computer Science 2015; 9012:268-276

49. Ambroziak W, Koziorowski D, Duszyc K, Górka-Skoczylas P,Potulska-Chromik A, Sławek J, Hoffman-Zacharska D.Genomic instability in PARK2 locus is associated with Parkinson’s disease. J Appl Genet.2015 Nov;56(4):451-61.

50. Laskowska IP, Gawryś L, Łęski S, Koziorowski D. Emotional processing in Parkinson's disease and schizophrenia: evidence for response bias deficits in PD. Front Psychol. 2015 Sep 24;6:1417.

51. Przybyszewski AW, Kon M, Szlufik S, Szymanski A, Habela P, KoziorowskiDM. Multimodal Learning and Intelligent Prediction of Symptom Development in Individual Parkinson's Patients.Sensors (Basel). 2016 14;16(9), pii:E1498. doi: 10.3390/s16091498.

52. Naruniec J., Wieczorek M, Szlufik S, Koziorowski D, Tomaszewski M, Kowalski M, Przybyszewski A. Webcam based system for video occulography. IET Computer Vision; 2016, doi:10.1049/iet-cvi.2016.0226

53. Agoniści dopaminy w leczeniu choroby Parkinsona i zespołu niespokojnych nóg - rekomendacje ekspertów Polskiego Towarzystwa Choroby Parkinsona i Innych Zaburzeń Ruchowych oraz Sekcji Schorzeń Pozapiramidowych Polskiego Towarzystwa Neurologicznego. Polski Przegląd Neurologiczny 2016; 12 (1)

54. Jarosław Sławek, Andrzej Bogucki, Sławomir Budrewicz, Artur Drużdż, Dariusz Koziorowski, Maciej Krawczyk, Stanisław Ochudło, MonikaRudzińska-Bar, Iwona Sarzyńska-Długosz. Leczenie toksyną botulinową spastyczności kończyny dolnej po udarze mózgu. Polski Przegląd Neurologiczny 2016;12(2):65-79

55. Kulinski R, Bauminger ER, Friedman A, Duda P, Galazka-Friedman J- Iron in typical and atypical parkinsonism – Mössbauer spectroscopy and MRI studies. Hyperfine Interactions 2016; 237: 4 doi.10.1007/s10751-016-1234-4

56. Puschmann A, Fiesel FC, Caulfield TR, Hudec R, Ando M, Truban D, Xu Hou X, Ogaki K, Heckman MG, James ED, Swanberg M, Jimenez-Ferrer I, Hansson O, Opala G, Siuda J, Boczarska-Jedynak M, Friedman A, Koziorowski D, Aasly JO, Lynch T, Mellick GD, Mohan M, Silburn PA, Sanotsky Y, Vilarino-Guell C, Farrer MJ, Li Chen L, Dawson VL, Dawson TM, Wszolek ZK, Ross OA , Springer W- Heterozygous PINK1 p.G411S increases risk of Parkinson’s disease via a dominant-negative mechanism. Brain 2016 doi:10.1093/brain/aww261